Interested parties encouraged to share views with task force examining effects of pharmaceutical mergers

From: Competition Bureau Canada

News release

U.S.-led consultation to inform joint project involving agencies from Canada, U.S., U.K. and European Union

May 11, 2021 – GATINEAU, QC – Competition Bureau

Through its participation in the Multilateral Pharmaceutical Merger Task Force, the Competition Bureau, with its counterparts in the U.S., the European Union and the U.K., is reviewing its approach to the analysis of pharmaceutical mergers.

The task force is seeking input from stakeholders to inform its review of a variety of issues related to mergers in the pharmaceutical industry, including potential new or refreshed theories of harm, the evaluation of the effects of a merger on innovation and potential remedies to resolve competition concerns.

The task force encourages stakeholders, including health policy experts, economists, attorneys, scientists, health care practitioners, academics, and consumers to share ideas that will lead to the development of future enforcement and policy efforts.

The U.S. Federal Trade Commission, will collect submissions on behalf of the task force. Interested parties can review the consultation questions and provide written comments to the U.S. FTC by following the instructions in its public request for comment.

For more information about the Bureau’s participation in the task force, interested parties may contact us at any time by submitting a request for information on the Bureau’s website.

Quick facts

  • Initiated by the U.S. FTC, the task force includes the Competition Bureau, the European Commission Directorate General for Competition, the U.K.’s Competition and Markets Authority, the U.S. Department of Justice, and Offices of State Attorneys General.

  • The task force builds on the strong working relationship the Competition Bureau has with its U.S., U.K. and European Union counterparts.

  • Promoting competition and innovation in Canada’s health sector, including the pharmaceutical industry, is a strategic priority for the Bureau.

Related products

Associated links

Contacts

For media enquiries, please contact:
Media Relations
Email: media-cb-bc@cb-bc.gc.ca

For general enquiries, please contact:
Enquiries | Complaints

Stay connected:
Twitter | Facebook | LinkedIn | YouTube | RSS Feed | Email Distribution List

The Competition Bureau, as an independent law enforcement agency, ensures that Canadian businesses and consumers prosper in a competitive and innovative marketplace.

Page details

Date modified: